HuProt™ Human Proteome Microarray v1.0
19,892 and counting! …the largest number of unique, full-length human proteins known to be included on a single slide, allowing thousands of interactions to be profiled in high-throughput. Here are just a few applications:
- protein-protein interactions
- protein-DNA/RNA binding
- antibody specificity
- protein-small molecule interaction
- biomarker discovery
- ubiquitylation substrate ID
HuProt™ Microarray Custom Discovery Services
Using the HuProt™ Microarray, CDI can do the work for you so you can concentrate on your research. We offer expertise in high-throughput design and analysis (as above) and provide detailed data analysis.
Developed an antibody? The specificity will be critical to the integrity of your research. HighSpec™ Antibody Validation is offered to assess cross-reactivity to over 17,000 human proteins BEFORE you publish.
Fast-MAb® Monoclonal Antibody Development
Need an antibody (and a GOOD one)? If other companies just aren’t cutting it from a specificity standpoint, please contact CDI regarding its Fast-MAb® monoclonal antibody production service. CDI will manufacture the antibody you need using the same proprietary process used in CDI mMAb™ antibodies INCLUDING HighSpec™ Antibody Validation. Just give us a call and we’ll get started!
mMAb™ Monoclonal Antibody
Vialed up, VALIDATED and ready to go. CDI is rapidly expanding its lineup of mouse monoclonal antibodies that are available for immediate shipment. Raised against human proteins, these affinity-purified monoclonals are application-tested for immunoblotting and immunoprecipitation, AND subjected to CDI’s HighSpec™ Antibody Validation for unprecedented specificity profiling. BE SPECIFIC! Visit our catalog for a listing of available antibodies.
The CDI mission is to empower research and development in proteomics with proprietary technologies, making possible — today — the protein discoveries of tomorrow. CDI protein microarrays and related services make possible rapid, efficient analysis of thousands of protein interactions while preserving valuable clinical samples. The Company’s microarray-powered monoclonal antibodies (MAbs) and MAb-related services provide unprecedented levels of specificity. The Company has locations in Baltimore, Maryland and in Mayaguez, Puerto Rico (PR).